03-01-2024 | Aortic Valve Replacement | Critical Appraisal of Trials
EVOLUT Low-Risk Trial data: “We see what we want to see!”
Author:
Pradeep Narayan
Published in:
Indian Journal of Thoracic and Cardiovascular Surgery
|
Issue 2/2024
Login to get access
Abstract
In the 4-year update of the EVOLUT Low-Risk Trial (NCT02701283), the authors highlight a non-significant improvement in the primary endpoint and a statistically significant, yet clinically irrelevant, enhancement in hemodynamics with transcatheter aortic valve replacement (TAVR) compared to surgical aortic valve replacement (SAVR). Overlooking the concurrent surgical procedures in SAVR patients, mortality rates remain similar at 4 years. Unaddressed is the substantial increase in permanent pacemaker implantations with TAVR and the fate of patients with paravalvular leaks.